Albireo Prices Public Offering of 4,000,000 Shares of Common Stock
September 09 2020 - 9:16PM
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan
pediatric liver disease company developing novel bile acid
modulators, announced today the pricing of its previously announced
underwritten public offering of 4,000,000 shares of its common
stock at a price to the public of $40.00 per share. Albireo’s gross
proceeds from this offering are expected to be $160 million, before
deducting underwriting discounts and commissions and offering
expenses. In addition, Albireo has granted the underwriters a
30-day option to purchase up to an additional 600,000 shares of
common stock at the public offering price, less underwriting
discounts and commissions. All of the shares in the offering are
being sold by Albireo. The offering is expected to close on or
about September 14, 2020, subject to satisfaction of customary
closing conditions.
Cowen and William Blair are acting as the joint
book-running managers and representatives of the underwriters for
the offering. Wedbush PacGrow, H.C. Wainwright & Co. and Baird
are acting as co-managers for the offering.
The offering is being made only by means of a
written prospectus and related prospectus supplement forming part
of a shelf registration statement on Form S-3 that was filed with
the Securities and Exchange Commission (SEC) on May 7, 2020 and
declared effective by the SEC on May 18, 2020. The preliminary
prospectus supplement and accompanying prospectus relating to and
describing the terms of the offering were filed with the SEC on
September 8, 2020. The final prospectus supplement and accompanying
prospectus will be filed with the SEC and will be available at the
SEC’s website located at www.sec.gov, copies of which may be
obtained, when available, from Cowen and Company, LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, Attn: Prospectus Department, by email at
PostSaleManualRequests@broadridge.com or by telephone at (833)
297-2926, or from William Blair & Company, L.L.C., Attention:
Prospectus Department, 150 North Riverside Plaza, Chicago, IL
60606, or by email at prospectus@williamblair.com or by telephone
at 1-800-621-0687.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or other jurisdiction in
which such an offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or other jurisdiction.
About Albireo
Albireo Pharma is a clinical-stage
biopharmaceutical company focused on the development of novel bile
acid modulators to treat orphan pediatric liver diseases, and other
liver and gastrointestinal diseases and disorders. Albireo’s lead
product candidate, odevixibat, is being developed to treat rare
pediatric cholestatic liver diseases and is in Phase 3 development
in progressive familial intrahepatic cholestasis (PFIC) and biliary
atresia, with a third Phase 3 trial being planned in Alagille
syndrome. Albireo was spun out from AstraZeneca in 2008. Albireo
Pharma is located in Boston, Massachusetts, and its key operating
subsidiary is located in Gothenburg, Sweden.
Forward-Looking Statements
This press release includes “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include statements,
other than statements of historical fact, regarding, among other
things, the completion and timing of the public offering and the
anticipated total gross proceeds from the offering. Albireo often
uses words such as “anticipates,” “believes,” “plans,” “expects,”
“projects,” “future,” “intends,” “may,” “will,” “should,” “could,”
“estimates,” “predicts,” “potential,” “planned,” “continue,”
“guidance,” and similar expressions to identify forward-looking
statements. Actual results, performance or experience may differ
materially from those expressed or implied by any forward-looking
statement as a result of various risks, uncertainties and other
factors, including, but not limited to: the completion of the
public offering and other risks and uncertainties that are
described under the heading “Risk Factors” in Albireo’s preliminary
prospectus supplement filed with the SEC on September 8, 2020,
Albireo’s most recent Annual Report on Form 10-K or in subsequent
filings that it makes with the Securities and Exchange Commission.
As a result of risks and uncertainties that Albireo faces, the
results or events indicated by any forward-looking statement may
not occur. Albireo cautions you not to place undue reliance on any
forward-looking statement. In addition, any forward-looking
statement in this press release represents Albireo’s views only as
of the date of this press release and should not be relied upon as
representing its views as of any subsequent date. Albireo disclaims
any obligation to update any forward-looking statement, except as
required by applicable law.
Investor Contact: Hans VitzthumLifeSci
Advisors, LLC617-430-7578
Media Contact:Colleen Alabiso, 857-356-3905,
colleen.alabiso@albireopharma.comClaire LaCagnina, 6 Degrees,
315-765-1462, clacagnina@6degreespr.com
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Apr 2023 to Apr 2024